Analysts Offer Predictions for AVTE FY2029 Earnings

Aerovate Therapeutics, Inc. (NASDAQ:AVTE) – Research analysts at Wedbush issued their FY2029 EPS estimates for shares of Aerovate Therapeutics in a research report issued to clients and investors on Monday, February 24th. Wedbush analyst L. Chico forecasts that the company will post earnings per share of ($0.74) for the year. The consensus estimate for Aerovate Therapeutics’ current full-year earnings is ($2.64) per share.

Aerovate Therapeutics Trading Down 0.8 %

Shares of Aerovate Therapeutics stock opened at $2.41 on Wednesday. Aerovate Therapeutics has a 12-month low of $1.25 and a 12-month high of $32.42. The firm’s 50 day simple moving average is $2.54 and its two-hundred day simple moving average is $2.34. The firm has a market capitalization of $69.59 million, a price-to-earnings ratio of -0.81 and a beta of 0.99.

Hedge Funds Weigh In On Aerovate Therapeutics

Hedge funds have recently made changes to their positions in the company. GTS Securities LLC acquired a new stake in Aerovate Therapeutics during the 4th quarter worth about $27,000. Squarepoint Ops LLC acquired a new stake in shares of Aerovate Therapeutics during the fourth quarter worth about $52,000. Two Sigma Advisers LP boosted its position in Aerovate Therapeutics by 38.5% in the fourth quarter. Two Sigma Advisers LP now owns 153,600 shares of the company’s stock valued at $407,000 after buying an additional 42,700 shares during the last quarter. Jefferies Financial Group Inc. purchased a new stake in Aerovate Therapeutics in the fourth quarter valued at approximately $1,590,000. Finally, Bridgeway Capital Management LLC acquired a new position in Aerovate Therapeutics in the 4th quarter worth approximately $159,000.

About Aerovate Therapeutics

Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.